Pharmafile Logo
Pharmafocus logo
Advanced Search

Targacept

Showing 9 posts of 9 posts found.

Targecept image

Targacept admits failure in Alzheimer’s trial

July 15, 2014
Research and Development, Sales and Marketing Alzheimer's, Aricept, Pfizer, TC-173, Targacept

Targacept is dropping a once promising Alzheimer’s drug from further clinical trials after it failed to beat Pfizer’s Aricept (donepezil) …

News
john_p

Targacept appoints chairman

January 28, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, richard

Clinical-stage biopharma firm Targecept has appointed its non-executive director since 2002 John Richard to be its chairman of the board. …

Appointment
steven_burrill-headshot-cropped

Targacept makes changes to Board and management

March 21, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept

Clinical-stage biopharma firm Targacept has announced several changes to its Board of directors and management. By the end of May …

Appointment
post-stephen-hill-targacept280

Targacept confirms Stephen Hill as president and chief executive

November 27, 2012
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, stephen hill

Clinical-stage biopharma firm Targacept has announced that Stephen Hill has been appointed as president and chief executive. Hill is expected …

Appointment

AstraZeneca to take Alzheimer’s drug into phase II

January 5, 2012
Research and Development Alzheimer's, AstraZeneca, Targacept

AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …

News
GlaxoSmithKline's London headquarters

GSK ends neuroscience research alliance

March 7, 2011
Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research

GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …

News

AZ-Targacept depression candidate moves into phase IIb

February 9, 2011
Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder

AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …

News

AstraZeneca and Targacept begin depression trials

June 24, 2010
Research and Development AstraZeneca, Targacept, depression

AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …

News
AlderleyHouseWebv

AZ licences late-stage depression candidate

December 8, 2009
Sales and Marketing AZ, Targacept, depression

AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025